Brean Murray, Carret & Co. is reiterating its Sell rating on shares of Medivation, Inc. MDVN.
“Medivation reported revenue of $16.6 million and EPS of ($0.11), neither of which is all that meaningful at Medivation's present stage,” Brean Murray, Carret & Co. writes. “The revenue constitutes the amortization of upfront payments made by Pfizer and Astellas, as per the collaboration agreements, and are being recognized on a straight-line basis until 2Q13 and 4Q14, respectively.”
Medivation closed Wednesday at $16.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in